Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5M7E

Tubulin-BKM120 complex

5M7E の概要
エントリーDOI10.2210/pdb5m7e/pdb
関連するPDBエントリー4O2B
分子名称Tubulin alpha-1B chain, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine, ... (13 entities in total)
機能のキーワードcell cycle, tubulin fold, cytoskeleton, microtubule
由来する生物種Rattus norvegicus (Rat)
詳細
細胞内の位置Cytoplasm, cytoskeleton: P81947 Q6B856
Golgi apparatus : P63043
タンパク質・核酸の鎖数6
化学式量合計265192.96
構造登録者
Bohnacker, T.,Prota, A.E.,Steinmetz, M.O.,Wymann, M.P. (登録日: 2016-10-27, 公開日: 2017-02-22, 最終更新日: 2024-01-17)
主引用文献Bohnacker, T.,Prota, A.E.,Beaufils, F.,Burke, J.E.,Melone, A.,Inglis, A.J.,Rageot, D.,Sele, A.M.,Cmiljanovic, V.,Cmiljanovic, N.,Bargsten, K.,Aher, A.,Akhmanova, A.,Diaz, J.F.,Fabbro, D.,Zvelebil, M.,Williams, R.L.,Steinmetz, M.O.,Wymann, M.P.
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Nat Commun, 8:14683-14683, 2017
Cited by
PubMed Abstract: BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ from BKM120 by only one atom. We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K. Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs. Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.
PubMed: 28276440
DOI: 10.1038/ncomms14683
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.046 Å)
構造検証レポート
Validation report summary of 5m7e
検証レポート(詳細版)ダウンロードをダウンロード

250059

件を2026-03-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon